Effect of CS-905(Azelnidipine) on Renal Function in Essential Hypertension.
|
Accession number;99A0447092
|
| Title;Effect of CS-905(Azelnidipine) on Renal Function in Essential Hypertension. |
| Author;
TOMITA KIMIO
(Tokyo Med. and Dent. Univ.)
NONOGUCHI HIROSHI
(Tokyo Med. and Dent. Univ.)
MARUMO FUMIAKI
(Tokyo Med. and Dent. Univ.)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.15;NO.3;PAGE.451-463(1999)
|
| Figure&Table&Reference;FIG.7, TBL.11, REF.21 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In 6 patients with mild to moderate essential hypertension CS-905(8-16mg once a day for 12 weeks) was evaluated for its hypotensive effect, safety, and effect on renal function. The results were as follows: 1) Both systolic and diastolic blood pressure were significantly decreased after treatment for 4 weeks and thereafter. A stable hypotensive effect was maintained for 12 weeks. 2) The glomerular filtration rate(GFR) decreased slightly in 2 patients and increased in the others, but no change was significant. 3) The renal plasma flow(RPF) increased in all patients, and the increase from the baseline was significant(p=0.021). 4) The filtration fraction(FF) remained uncharged, with a significant in renal blood(RBF) (p=0.044) and a significant decrease in renovascular resistance(RVR) (p=0.009). 5) There were no significant changes in the plasma levels of renin, aldosterone, angiotensin I, or angiotensin II. 6) Abdominal pain occurred in one patient, but it was regarded as an incidental finding which was not related to CS-905. There were no other symptoms or abnormal laboratory values, nor were there any complications. Consequently, CS-905 caused no safety problems. These results suggest that administration of CS-905 has no adverse effects on renal function, nor any effect on the renin-angiotensin system secondary to stimulation of the adrenergic nevous system. (author abst.) |
|
|
|
Related Articles;
|
|
